FGFR3 alterations are a prevalent potential driver in oncology, with continuous activation of the FGFR signalling pathway driving multiple tumourigenic processes across tumour types.[1][2][3][4] As altered FGFR signalling is common in a wide variety of cancers, FGFR alterations represent an important potential target for treatment.[3]
FGFR3 alterations are most commonly found in UC and have been identified across all grades and/or stages of bladder cancer[3][5]
All in all, the molecular biomarkers and pathways involved in UC are key to understanding its biological heterogeneity and identifying specific subtypes, which may be used to predict treatment outcomes.[6] Therefore, a focus on the distinct molecular subtypes in UC could help you see your individual LA/mUC patients more clearly.[7]
Discuss available biomarkers and related molecular testing options with your pathologist today to better understand your patients’ tumour growth drivers[8][9]
FGFR: fibroblast growth factor receptor; LA: locally advanced; mUC: metastatic UC; UC: urothelial carcinoma.